Another approach involves TGF-β gene silencing with trabedersen (an antisense oligonucleotide specific for TGF-β2 mRNA) which reduced tumor growth in a PDAC mouse model [176] and was suggested to have possible efficacy in a phase I trial [177]. The gene discussed is TGFB2; the disease is neoplasm.